Cleveland BioLabs and Roswell Park Cancer Institute

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cleveland BioLabs and Roswell Park Cancer Institute Announce Award of Department of Defense Breast Cancer Research Program Breakthrough Grant for Entolimod

BUFFALO, NY--(Marketwired - Apr 27, 2015) - Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) and Roswell Park Cancer Institute (RPCI) today announced the award of a three-year, $1.2 million Breast Cancer Research Program Breakthrough Award to Roswell Park from the Department of Defense Congressionally Directed Medical Research Program for research into the immunotherapy of metastatic breast cancer with entolimod, a toll-like receptor 5 (TLR5) agonist. The intent of the Breakthrough Award is to support promising research that has potential to lead to or make breakthroughs in breast cancer therapy.

Breast cancer is one of the most common cancers in women worldwide. 1 Nearly 50% of women diagnosed with breast cancer will progress to liver and lung metastatic disease. 2 The 5-year survival rate for metastatic breast cancer is currently estimated at less than 25%. 3 Current anti-cancer therapies show limited efficacy against metastatic breast cancer and often display significant toxicities. Entolimod, a proprietary investigational drug being developed by CBLI, has shown preclinical potential in the immunotherapy of cancer, including models of liver metastases. Entolimod administration activates innate and adaptive immune responses and mobilizes immunocytes to organs and tumors that express entolimod's target, TLR5.

A Phase 1 open-label, dose-escalation trial of entolimod in patients with advanced cancer was completed in September 2014 at Roswell Park Cancer Institute. Findings will be presented during the Developmental Therapeutics - Immunotherapy poster session at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO) on May 30, 2015. A second Phase 1 study of entolimod in patients with advanced cancer is enrolling in the Russian Federation to expand upon clinical observations made at the higher dose levels in the RPCI study and to gather further statistics on immune response to administrations of entolimod.

Andrei Gudkov, Ph.D., D.Sci. , Senior Vice President of Basic Science at Roswell Park Cancer Institute, Chief Scientific Officer of Cleveland BioLabs, and Principal Investigator on the grant, stated, "We are honored to be among less than 5% of the highest scored applications awarded with this very competitive grant and are excited to further our research into the potential utility of entolimod in treating breast cancer. We expect that the Breakthrough Award will support several avenues of research, including characterization of the immune response elicited by administrations of entolimod in a pre-clinical model of metastatic breast cancer and in patients with metastatic breast cancer being enrolled in an ongoing clinical study in the Russian Federation. We also plan to explore entolimod's ability to improve the therapeutic efficacy of a tumor-specific dendritic cell vaccine in animal models."

References 1 Society, A. C. Cancer Facts & Figures 2014. (American Cancer Society, Atlanta, 2014). 2 Berkowitz, N., Gupta, S. & Silberman, G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 3, 23-30, doi:10.1046/j.1524-4733.2000.31003.x (2000). 3 National Cancer Institute. SEER Stat Fact Sheets: Breast. http://seer.cancer.gov/statfacts/html/breast.html .

About Cleveland BioLabs, Inc. Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as a potential cancer treatment. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and through two joint ventures, Panacela Labs, Inc. and Incuron, LLC. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com .

About Roswell Park Cancer Institute The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org , call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org . Follow Roswell Park on Facebook and Twitter.

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words and phrases such as "plan," "potential," "will," "expect" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the conduct and results of our various clinical trials; the efficacy of our therapeutic products; our ability to successfully complete planned clinical studies; and our ability to obtain regulatory approval for our therapeutic products. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

These factors include, among others, the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's collaborative relationships and the financial risks related thereto; the Company's ability to comply with its obligations under license agreements; subsequent changes in the agreement with the Russian Ministry of Industry and Trade; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company's need for substantial additional financing to meet its business objectives; and the potential for the loss of funding from the Company's R&D grants and contracts and its ability to win additional funding under such grants and contracts. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.

Contacts: Cleveland BioLabs, Inc. Rachel Levine Vice President, Investor Relations T: 917-375-2935 E: rlevine@cbiolabs.com Roswell Park Cancer Institute Annie Deck-Miller Senior Media Relations Manager T: 716-845-8593 E: annie.deck-miller@roswellpark.org

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 27

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 107

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 190

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 64

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 119

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 152

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 41

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 56

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading

Top 5 Most Recently Viewed Articles

Legacy of Lovers Unveils Transformative Single Addition

Updated Category News Views 154

Legacy of Lovers Launches New Musical Journey with 'Calm Cool Connection' With an exciting new release, Endless Love embraces the future of music with their single 'Calm Cool Connection'. This dynamic piece captures the essence of personal transformation and encourages listeners to embrace their own journeys. The track stands out, infused with bright melodies and...

Continue Reading
Major Shareholding Update for Park Street A/S Shareholders

Updated Category News Views 162

Significant Shareholding Announcement Park Street A/S is making headlines with its recent announcement regarding major shareholder developments. The company, a key player in its industry, has disclosed essential updates about the share capital and voting rights held by Park Street Asset Management Ltd., a trusted partner in managing its shareholding. Capital Reduction and...

Continue Reading
Alamos Gold's Robust Quarterly Dividend and Strategic Buybacks

Updated Category News Views 150

Quarterly Dividend Announcement by Alamos Gold All figures mentioned are in United States dollars unless specified otherwise. In a recent announcement, Alamos Gold Inc. (TSX:AGI; NYSE:AGI) has revealed a significant update regarding its shareholder value strategies. The Company’s Board of Directors has declared a quarterly dividend of US$0.025 per common share. This...

Continue Reading
AITX Expands Innovative Logistics Solutions with ROAMEO

Updated Category News Views 98

Revolutionizing Logistics with AITX and ROAMEO In an ever-changing world of logistics, AITX’s Robotic Assistance Devices, Inc. (RAD) is stepping up to the plate with new solutions that elevate operational efficiency and security standards. The company has honed its focus on creating tailored solutions for the logistics sector, which is widely acknowledged for its...

Continue Reading
BlackRock's Bold Bet on Bitcoin Amid Microsoft's Hesitation

Updated Category News Views 131

BlackRock's Investment Insights Into Bitcoin Microsoft Corp. (NASDAQ: MSFT) recently made headlines when it decided against exploring Bitcoin as a potential investment. Despite this, its significant shareholder, BlackRock, is making waves with its strong backing for the leading cryptocurrency. Known for its strategic investments, BlackRock's optimism presents a stark...

Continue Reading